IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced that William Ho, Chief Executive Officer and co-founder of IN8bio, will present a company overview as well as participate on an Oncology panel at BioFuture 2021. Kate Rochlin, Vice President, Operations and Innovation of IN8bio, will present on the company’s gamma delta T-cell programs in Oncology at the Advanced Therapies Congress & Expo 2021.
| Event: | BioFuture 2021 |
| Presentation: | Company In person presentation |
| Date: | October 5 |
| Time: | 10:30 a.m. EDT |
| Location: | Room -A (ninth floor), Cure, 345 Park Avenue South, New York City |
| Presentation: | Panel: Next Gen Oncology Therapeutics: Changing the Cancer Landscape |
| Date: | October 5 |
| Time: | 1:30 p.m. EDT |
| Location: | Salon 3 |
| Event: | Advanced Therapies Congress & Expo 2021 |
| Date: | October 5 |
| Presentation: | Presentation: The development of gamma delta T-cells for cell therapy in Oncology |
| Time: | 11:30 a.m. EDT |
| Location: | ExCel Conference Center, London, In person |
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product candidates for solid and liquid tumors. Gamma-delta T-cells are a specialized population of T-cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.
IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T-cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.
For more information about IN8bio and its programs, please visit www.IN8bio.com.
Company Contact:
IN8bio, Inc.
Kate Rochlin, Ph.D.
+1 646.600.6GDT (6438)
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
Solebury Trout
David Buck
+ 1 646.378.2927
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Burns McClellan, Inc.
Robert Flamm, Ph.D. / Harrison Wong
+1 212.213.0006 - ext. 364 / 316
This email address is being protected from spambots. You need JavaScript enabled to view it. / This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.33 |
| Daily Change: | -0.04 -10.87 |
| Daily Volume: | 802,613 |
| Market Cap: | US$23.770M |
December 02, 2024 November 25, 2024 November 12, 2024 November 12, 2024 November 05, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
